about
Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitorPreparative purification of recombinant proteins: current status and future trendsBiochemical and physical characterisation of urinary nanovesicles following CHAPS treatmentN-linked (N-) glycoproteomics of urinary exosomes. [Corrected].Changes in plasma protein levels as an early indication of a bloodstream infection.Heparin and heparin binding proteins: potential relevance to reproductive physiology.Human Spermatozoa Quantitative Proteomic Signature Classifies Normo- and Asthenozoospermia.N-Glycoproteomics of Human Seminal Plasma Glycoproteins.Oral squamous cell carcinoma patients can be differentiated from healthy individuals with label-free serum proteomics.Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis.Glycosylation patterns of kidney proteins differ in rat diabetic nephropathy.N-linked (N-) Glycoproteomics of Urinary Exosomes.Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets.Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics.Quantitative N-glycoproteomics reveals altered glycosylation levels of various plasma proteins in bloodstream infected patients.Human serum albumin as a new interacting partner of prolactin inducible protein in human seminal plasmaRecovery of urinary nanovesicles from ultracentrifugation supernatantsPlasma protein expression differs between colorectal cancer patients depending on primary tumor location
P50
Q24303274-597A5EC9-ACAC-4735-BB41-6A974C39D984Q27008176-6352188F-9C97-4D3F-B4F6-B3EEA524472EQ28481298-6B0694CB-038B-49E2-AC77-46F602D6E762Q35148535-2BD0AD9F-F84D-4BD1-BBCA-DA471D81F597Q36290244-3F251182-A39C-42F4-9B80-F2B2CB6D73B6Q38084709-1F4F5C39-74BD-429A-81B2-DE85D09970CFQ38384127-7BFADEE2-65A5-4BA9-AF22-D3EE044E4E9EQ38452042-6E57F72F-A323-493D-A897-530AEDB87A70Q38717277-C0782879-16BC-4FDC-A0B7-BCD224FE7767Q40975840-E66DBCF6-7DC7-49B9-A118-9725610BCA32Q41584202-AEDB6695-EF5F-430C-B54A-5F81027FA9CFQ42425478-B983191C-2B06-4CE5-A700-4F1C1346EDA5Q47660739-A00B199F-B0AC-40FF-9E17-FB7801DD388FQ52598780-8FF6C131-3DD5-472E-9569-A1C4845CA963Q52622048-C60BF074-30AC-4D72-B429-04EB3D65C579Q58805924-01CCE6C8-F134-4D41-8FD4-AB055D0BFF6EQ85758636-5D6F8942-AA6B-4B45-8FAA-1D6AFF416DD8Q95840338-4598878F-A426-430C-A2E9-E8BD3784D9D9
P50
description
researcher ORCID ID = 0000-0002-5021-8150
@en
wetenschapper
@nl
name
Mayank Saraswat
@ast
Mayank Saraswat
@en
Mayank Saraswat
@es
Mayank Saraswat
@nl
type
label
Mayank Saraswat
@ast
Mayank Saraswat
@en
Mayank Saraswat
@es
Mayank Saraswat
@nl
prefLabel
Mayank Saraswat
@ast
Mayank Saraswat
@en
Mayank Saraswat
@es
Mayank Saraswat
@nl
P106
P1153
36560152900
P31
P496
0000-0002-5021-8150